Ads

You May Also Like

Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company

-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and ...

Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO

CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical ...